Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 414-420-0 | CAS number: - SPE 93279
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- February-October 2005
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Well performed and reported study according to standard/guideline.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 006
- Report date:
- 2006
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3700 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- .alpha.-D-Glucopyranoside, 2-ethylhexyl
- Cas Number:
- 125590-73-0
- IUPAC Name:
- .alpha.-D-Glucopyranoside, 2-ethylhexyl
- Reference substance name:
- A mixture of: 2-ethylhexyl mono-D-glucopyranoside; 2-ethylhexyl di-D-glucopyranoside
- EC Number:
- 414-420-0
- EC Name:
- A mixture of: 2-ethylhexyl mono-D-glucopyranoside; 2-ethylhexyl di-D-glucopyranoside
- Cas Number:
- 125590-73-0
- Molecular formula:
- (C6H10O5)n, C8H18O n = 1,2
- IUPAC Name:
- Reaction mass of 2-ethylhexyl mono-D-glucopyranoside and 2-ethylhexyl di-D-glucopyranoside
- Details on test material:
- Name of test compound: SPE 93279
Batch no.: 3001036216
Appearance: Liquid
Purity: solids: ca. 64.7%, water 35.3%
Storage: at room temperature (20±5 degr. C), away from direct sunlight
Expiry date: 31 October 2005
Stability in the vehicle: stable for at least 4 h
Constituent 1
Constituent 2
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: RCC Ltd., Fuellinsdorf Switzerland
- Age at study initiation: 11 weeks (at pairing)
- Weight at study initiation: 191-234 g
- Fasting period before study: not applicable
- Housing: individually in type-3 Macrolon cages
- Diet (e.g. ad libitum): ad lib
- Water (e.g. ad libitum): ad lib
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): target 22±3
- Humidity (%): target: 30-70
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From:26 February (delivery of the animals) To: 24 March 2005
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item was weighed into a glass beaker on a tared precision balance and the vehicle (Milli-Q-Water) added (wlv). The vehicle was heated to approx. 30°C before addition to the test item to dissolve crystal formation in the formulation. Using an appropriate
homogenizer a homogenous mixture was prepared. Having obtained a crystal-free, homogenous mixture (determined visually), the dose formulations were left at room temperature until dosing. During the daily administration period homogeneity of the test item in
the vehicle was maintained using a magnetic stirrer.
Dose formulations were prepared daily, no longer than 4 hours prior to dosing.
VEHICLE
- Justification for use and choice of vehicle (if other than water): water was used
- Concentration in vehicle: not indicated
- Amount of vehicle (if gavage): 5 mL/kg
A correction factor of 1.55 was used for the preparation of the dose formulations to adjust for the purity of the test compound. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples for determination of concentration, homogeneity and stability (4 hours) of the dose formulations were taken during the first week of the administration period. Additionally, samples for determination of concentration and homogeneity were taken during the
last week of the administration period. On each occasion three samples of approximately 2 g were taken from the top, middle and
bottom of each formulation and transferred into flat bottomed flasks. Stability samples were taken from the middle only. The samples were frozen (-25°C to -15°C) pending analysis. Samples were sent on dry ice to Dr. D. Flade, RCC Ltd, Environmental Chemistry &
Pharmanalytics, CH-4452 ltingen / Switzerland. Analysis was performed using LC/MS (although in the main part of the report it was
indicated that analyses had been performed using HPLC). - Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused:
- M/F ratio per cage: 1:1
- Length of cohabitation: animals were housed in special automatic mating cages (with synchronized timing to initiate the nightly
mating period), until evidence of copulation
- After ... days of unsuccessful pairing replacement of first male by another male with proven fertility. No info.
- Further matings after two unsuccessful attempts: no info
- Verification of same strain and source of both sexes: yes
- Proof of pregnancy:vaginal plug or sperm in vaginal smear referred to as day 0 of pregnancy - Duration of treatment / exposure:
- from day 6 to day 20 (inclusive) post coitum
- Frequency of treatment:
- daily
- Duration of test:
- 21 days
Doses / concentrationsopen allclose all
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 250 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 22 females per dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: based on RF study using 0, 50, 250 and 600 mg/kg bw/day. 600 mg/kg resulted in 60% (3/5) mortality
- Rationale for animal assignment (if not random): mated rats were assigned to the different groups using a computer-generated random algorithm
:
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: daily from day 0 to day 21 post coitum
FOOD CONSUMPTION: Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Time schedule: at 3-day intervals
WATER CONSUMPTION: No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 21
- Organs examined: all internal organs
Post mortem examination, including gross macroscopic examination of all internal organs, with emphasis on the uterus, uterine
contents, position of fetuses in the uterus and number of corpora lutea, was performed and the data recorded. The uteri (and
contents) of all females with live fetuses were weighed at necropsy on day 21 post coitum to enable the calculation of the
corrected body weight gain. From all females the following organs were preserved in neutral phosphate buffered 4% formaldehyde solution for possible future examination: trachea, lungs, heart and liver. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: - Fetal examinations:
- - External examinations: Yes (all per litter)
- Soft tissue examinations: Yes (half per litter)
- Skeletal examinations: Yes (half per litter)
- Head examinations: Yes ( half per litter) - Statistics:
- The following statistical methods were used to analyse body weights, food consumption, reproduction and skeletal examination
data:
- Means and standard deviations of various data were calculated.
- If the variables could be assumed to follow a normal distribution, the Dunnett many-one t-test, based on a pooled variance
estimate, was used for intergroup comparisons (i.e. single treatment groups against the control group).
- The Steel test (many-one rank test) was applied when the data could not be assumed to follow a normal distribution.
- Fisher's Exact test for 2x2 tables was applied if the variables could be dichotomized without loss of information.
References:
C.W. Dunnett A Multiple Comparison Procedure for Comparing Several Treatments with a Control,
J. Amer. Statist. Assoc. 50, 1096-1 121 (1 955).
R. G. Miller Simultaneous Statistical Inference, Springer Verlag, New York (1981).
R.A. Fisher Statistical Methods for Research Workers, Oliver and Boyd, Edinburgh (1 950). - Indices:
- Pre and post-implantation losses
- Historical control data:
- Included in the report
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
Clinical signs: in the high dose group, one female (No. 85) was found dead on day 18 post coitum. All other females survived until
scheduled necropsy. For two females in this group, rales were noted on single days of the treatment period. Although it was an
isolated mortality and the incidence of this clinical sign was very low, both were considered to be test item related, since mortalities and rales have been repeatedly noted in other rat studies with this test item.
Food intake: in the high dose group, mean food consumption was transiently slightly reduced after the onset of treatment. After the first six days of treatment mean food consumption recovered to values similar to those of the vehicle control.
Body weight: mean absolute body weights and body weight gain were not affected by treatment with the test item at any dosage.
Mean corrected body weight gain (corrected for gravid uterus weight) was similar in all groups and gave no indication of a test item-related effect.
Reproduction data: The relevant reproductive parameters (incidence of post-implantation loss and number of fetuses per dam)
were similar in all groups and gave no indication of a test item-related effect.
Necropsy: During macroscopic examination no findings that were considered to be test item-related were noted.
Effect levels (maternal animals)
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 250 mg/kg bw/day
- Basis for effect level:
- clinical signs
- necropsy findings
- other: maternal toxicity
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- External malformations:
- no effects observed
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- During skeletal examination of the fetuses abnormal findings were noted in:
14 out of 124 examined fetuses (in 10 litters) in the control group
11 out of 114 examined fetuses (in 10 litters) in the low dose group
5 out of 136 examined fetuses (in 4 litters) in the mid dose group
15 out of 124 examined fetuses (in 10 litters) in the high dose group.
In the high dose group, a marginal incidence of wavy ribs (3 fetuses affected compared with 0 fetuses in the vehicle control) was noted. Since this incidence of wavy ribs was in the range of historical control data this finding was considered to reflect the range of natural variability. The findings noted mainly comprised common findings such as fused zygomatic arches and displaced pelvic girdles. Neither type nor frequency of these abnormal findings was considered to be test item-related. - Visceral malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- During visceral examination of fetuses abnormal findings were noted in:
52 out of 135 examined fetuses (in 21 litters) in the control group
42 out of 122 examined fetuses (in 19 litters) in the low dose group
53 out of 149 examined fetuses (in 18 litters) in the mid dose group
53 out of 137 examined fetuses (in 20 litters) in the high dose group.
Types and incidences of abnormal findings (such as lenticular lesion of the eye, elongated thymus, thinned diaphragm, left sided umbilical artery and displaced testis) in the low, mid and high dose groups were similar to those noted in the vehicle control and gave no indication of test item-related effects. In the high dose group, one fetus (No. 540) with multiple cranial findings and one fetus (No. 91) with situs inversus, displaced kidneys and abnormal lung lobulation were noted. These isolated findings were considered to be not test item-related. In all four groups, discoloured head regions were observed, which were most probably fixation artefacts. - Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
There were no treatment-related embryotoxic effects (see below for a complete summary).
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- >= 500 mg/kg bw/day
- Basis for effect level:
- changes in sex ratio
- external malformations
- skeletal malformations
- visceral malformations
- other: developmental toxicity
Fetal abnormalities
- Key result
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Key result
- Developmental effects observed:
- not specified
Any other information on results incl. tables
SEX RATIOS
No test item-related effects on the sex ratio of fetuses were noted in any group, which were always close to 50% each.
BODY WEIGHTS
Mean fetal body weights were similar in all groups and gave no indication of a test item-related effect.
EXTERNAL EXAMINATION
No abnormalities were noted during external examination of fetuses. In the high dose group, agnathia inferior, astomia and reduction or absence of the eyes were noted for one fetus (No. 540, dam 73). This isolated finding was considered to be incidental.
VISCERAL EXAMINATION (MICRODISSECTION TECHNIQUE)
During visceral examination of fetuses abnormal findings were noted in:
52 out of 135 examined fetuses (in 21 litters) in the control group
42 out of 122 examined fetuses (in 19 litters) in the low dose group
53 out of 149 examined fetuses (in 18 litters) in the mid dose group
53 out of 137 examined fetuses (in 20 litters) in the high dose group.
Types and incidences of abnormal findings (such as lenticular lesion of the eye, elongated thymus, thinned diaphragm, left sided umbilical artery and displaced testis) in the low, mid and high dose groups were similar to those noted in the vehicle control and gave no indication of test item-related effects. In the high dose group, one fetus (No. 540) with multiple cranial findings and one fetus (No. 91) with situs inversus, displaced kidneys and abnormal lung lobulation were noted. These isolated findings were considered to be not test item-related. In all four groups, discoloured head regions were observed, which were most probably fixation artefacts.
ABNORMAL FINDINGS FROM FETAL SKELETAL EXAMINATION
During skeletal examination of the fetuses abnormal findings were noted in:
14 out of 124 examined fetuses (in 10 litters) in the control group
11 out of 114 examined fetuses (in 10 litters) in the low dose group
5 out of 136 examined fetuses (in 4 litters) in the mid dose group
15 out of 124 examined fetuses (in 10 litters) in the high dose group.
In the high dose group, a marginal incidence of wavy ribs (3 fetuses affected compared with 0 fetuses in the vehicle control) was noted. Since this incidence of wavy ribs was in the range of historical control data this finding was considered to reflect the range of natural variability. The findings noted mainly comprised common findings such as fused zygomatic arches and displaced pelvic girdles. Neither type nor frequency of these abnormal findings was considered to be test item-related.
SKELETAL EXAMINATION OF FETUSES - STAGE OF DEVELOPMENT AND COMMON VARIANTS
Examination of the stage of development revealed that the right and left toes (toes 2, 3 and 4, proximal phalanx, respectively) were statistically significantly less ossified in the high dose group than in the vehicle control both calculated on a litter and fetus basis. However, this finding was
considered not to be test item-related given that, in control fetuses, ossification of these structures, as judged by both the extent and depth of alizarin staining, was poor, and there were no other findings that were suggestive of delay in ossification.
CARTILAGE EXAMINATION OF FETUSES (ABNORMAL FINDINGS AND COMMON VARIANTS)
During cartilage examination of the fetuses abnormal findings were noted in:
0 fetuses (in 0 litters) in the control group
2 fetuses (in 2 litters) in the low dose group
0 fetuses (in 0 litters) in the mid group 3
1 fetus (in 1 litter) in the high dose group.
The findings noted were common cartilaginous abnormalities such as offset costal cartilages, cervical vertebra with additional ventral plate and fused lumbar vertebral bodies. Neither the types nor the frequencies of these findings gave any indication of test item-related effects. When calculated on a litter basis, the incidence of branched xiphoid cartilage in the low dose group was statistically significantly lower than in the vehicle control. When calculated on a fetus basis, the incidence of a longer costal cartilage in the low dose group was statistically significantly higher. Both
incidences of common variations were considered to be of no toxicological relevance.
Applicant's summary and conclusion
- Conclusions:
- Based on the results of the present study, the NOEL (no observed effect level) for maternal toxicity was considered to be 250
mg/kg body weight/day, the NOEL for developmental toxicity was 500 mg/kg body weight/day. - Executive summary:
The purpose of this study was to assess the effects of SPE 93279 on the pregnant female and on embryonic and fetal development when administered orally by gavage once daily to mated female rats from day 6 through to day 20 post coitum, inclusive. Each group consisted of 22 mated female rats. SPE 93279 was administered once daily at dose levels of 0, 50, 250 and 500 mg/kg body weight/day. A standard dose volume of 5 mL/kg body weight with a daily adjustment to the actual body weight was used. Control animals were dosed with the vehicle alone (Milli-Q-Water). All surviving females were sacrificed on day 21 post coitum and the fetuses were removed by Caesarean section. Examination of dams and fetuses was performed in accordance with international recommendations.
Maternal toxicity:
At 500 mg/kg body weight/day, one female (No. 85) was found dead on day 18 post coitum. All other females survived until scheduled necropsy. For two females at 500 mg/kg body weight/day rales were noted on single days of the treatment period. Although it was an isolated mortality and the incidence of this clinical sign was very low, both were considered to be test item-related, since mortalities and rales have been repeatedly noted in other rat studies with this test item. At 500 mg/kg body weight/day, mean food consumption was transiently slightly reduced only after the onset of treatment. Mean food consumption at 50 and 250 mg/kg body weight/day was not affected by treatment with the test item. No test item-related effects on body weight gain were noted. The relevant reproductive parameters (incidence of post-implantation loss and number of fetuses per dam) were similar in all groups and gave no indication of a test item-related effect. There were no treatment-related changes at necropsy.
Fetal toxicity:
Mean fetal body weights were similar in all groups and gave no indication of a test item-related effect. No abnormalities were noted during external examination of fetuses. No indication of test item-related effects was noted during the visceral examination. During skeletal examination, no findings that were considered to be test item-related were noted.
Overall, treatment with the test item at 500 mg/kg body weight/day resulted in rales in two females and in the death of one animal. Since mortalities and rales were also noted in other rat studies, including the RF study at 600 mg/kg bw, both were considered to be test item-related. Based on these results the NOEL (no observed effect level) for maternal toxicity was considered to be 250 mg/kg body weight/day, the NOEL for developmental toxicity was established at the high dose level of 500 mg/kg body weight/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.